Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) EBIT Margin (2021 - 2025)

InMed Pharmaceuticals has reported EBIT Margin over the past 5 years, most recently at 256.36% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 5360.0% year-over-year to 256.36%; the TTM value through Dec 2025 reached 174.87%, down 1205.0%, while the annual FY2025 figure was 160.77%, 1750.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 256.36% at InMed Pharmaceuticals, down from 162.54% in the prior quarter.
  • Over five years, EBIT Margin peaked at 20.99% in Q2 2023 and troughed at 1626.64% in Q4 2021.
  • A 5-year average of 450.84% and a median of 202.75% in 2024 define the central range for EBIT Margin.
  • Biggest five-year swings in EBIT Margin: skyrocketed 124562bps in 2023 and later tumbled -13755bps in 2024.
  • Year by year, EBIT Margin stood at 1626.64% in 2021, then skyrocketed by 71bps to 471.26% in 2022, then skyrocketed by 72bps to 132.64% in 2023, then tumbled by -53bps to 202.75% in 2024, then fell by -26bps to 256.36% in 2025.
  • Business Quant data shows EBIT Margin for INM at 256.36% in Q4 2025, 162.54% in Q3 2025, and 139.49% in Q2 2025.